Updated:
Immunic
Immunic, led by CEO Daniel Vitt since 2016, runs a Phase 3 oral MS pipeline from New York and Gräfelfing, Germany.
Immunic
Immunic was founded in 2016 and is headquartered in New York, with its core research operations based in Gräfelfing, Germany. CEO Daniel Vitt and CFO Glenn Whaley lead the company, which has raised capital through public equity offerings on Nasdaq and strategic partnerships, including a notable collaboration with the Multiple Sclerosis Center at the University of California, San Francisco to explore its therapeutic pipeline (per the company, 2021). The wealth backing Immunic is not family-origin but institutional: its capitalization comes from public investors and dedicated life-science funds. The company's strategy concentrates exclusively on oral small-molecule drugs for chronic inflammatory and autoimmune diseases. Its lead candidate, vidofludimus calcium, is a selective immune modulator in Phase 3 trials for relapsing and progressive multiple sclerosis. A second clinical asset, IMU-856, is being investigated for celiac disease and targets restoration of intestinal barrier function. Immunic's pipeline is supported by a third, preclinical program aimed at inflammatory bowel disease. The firm conducts trials across the United States and Europe, maintaining a geographic focus on major pharmaceutical markets. Immunic disclosed $95.3 million in cash and equivalents at the close of 2025, providing a runway that extends through key Phase 3 data readouts (per the company, March 2026). The team maintains a lean operational footprint, with senior leadership split between New York and the Munich-area research hub. In addition to its clinical collaborations, Immunic has engaged with patient advocacy groups to shape trial design for progressive MS, a historically underserved segment. January 2026: Immunic presented preclinical data supporting a potential expansion of the vidofludimus calcium program into epilepsy, signaling a broader neurological strategy (per the company, January 2026). Structurally, Immunic diverges from the typical single-asset biotech by operating a true transatlantic clinical organization rather than an outsourced development model. The company's German research subsidiary provides direct control over medicinal chemistry and early clinical work, while the New York headquarters manages Nasdaq compliance and institutional investor relations. This integration of European R&D with U.S. capital markets access defines both its cash-efficient development path and its regulatory strategy for dual FDA-EMA submissions.
General information
Firm type
Asset Manager
Year founded
2016
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
Gräfelfing, Germany
Principals
Daniel Vitt
Chief Executive Officer
Glenn Whaley
Chief Financial Officer
Sector focus
Frequently asked questions
What is the mechanism of action for Immunic's lead drug candidate?
Vidofludimus calcium acts as a selective immune modulator by inhibiting dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme required for the proliferation of activated T and B lymphocytes. Unlike high-dose DHODH inhibitors historically used in oncology, this compound is designed to partially suppress autoimmune activity without causing broad immunosuppression. The approach targets both relapsing and progressive forms of multiple sclerosis.
Why does Immunic maintain a dual headquarters structure between New York and Germany?
The Gräfelfing, Germany location serves as the operational research and development center, housing Immunic's medicinal chemistry and early clinical operations. The New York headquarters provides access to U.S. institutional capital markets, Nasdaq compliance infrastructure, and proximity to the FDA during regulatory submissions. This dual structure lets Immunic manage European R&D costs while tapping American biotech liquidity.
What distinguishes vidofludimus calcium from other oral MS treatments?
Vidofludimus calcium targets neurofilament light chain (NfL) reduction as a primary endpoint, aiming to demonstrate direct neuroprotective effects beyond relapse suppression. Competitor oral MS drugs — such as dimethyl fumarate and fingolimod — were approved principally on relapse-rate reduction. If successful, Immunic's Phase 3 ENSURE and ENHANCE trials would be the first to demonstrate neuroprotection as a labeled benefit in progressive MS.
Is Immunic affiliated with a larger pharmaceutical group or controlled by a founder's family office?
No. Immunic is a fully independent, publicly traded clinical-stage biotech. It is not controlled by a founder's family office, nor is it a subsidiary of a larger pharmaceutical company. Institutional investors and life-science-focused funds provide the bulk of its equity backing through Nasdaq offerings.
What cash runway does Immunic currently have, and how does it affect the investment thesis?
Immunic reported $95.3 million in cash and equivalents as of December 31, 2025, which management projects will fund operations through key Phase 3 MS data readouts. This capital position removes immediate dilution risk ahead of binary clinical catalysts. The runway is continually assessed against burn rate, with additional capital likely needed for pre-commercialization if trials succeed (per the company, March 2026).
Which autoimmune indications does Immunic explicitly avoid targeting?
Immunic has publicly focused its pipeline on multiple sclerosis, celiac disease, and inflammatory bowel disease. The company has not announced programs in rheumatoid arthritis, lupus, or dermatological autoimmune conditions, distinguishing its focus from many peers in the immunology space.
Who holds decision-making authority over Immunic's clinical strategy?
CEO Daniel Vitt, who holds both a PhD in pharmacology and an MBA, has ultimate decision-making authority over clinical strategy and capital allocation, reporting to the board of directors. The board includes institutional investor representatives. Day-to-day clinical development decisions are executed by the Chief Medical Officer in coordination with the German research leadership.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: